PSA nadir and outcome in 100 patients with pT3b prostate cancer

Pietro Pepe, Giuseppina Improta, Filippo Fraggetta, Carmela Emmanuele, Vittorio Simeon, Giuseppe Dibenedetto, Maurizio Colecchia, Francesco Aragona

Research output: Contribution to journalArticle


Aim: The prostate-specific antigen (PSA) nadir and long-term outcome in patients with pT3b prostate cancer were evaluated. Patients and Methods: From July 2000 to December 2012, in 100 patients (median age=62 years) with pT3b prostate cancer following radical retropubic prostatectomy (RRP) preoperative and pathological findings predictive of PSA nadir (≤0.2 vs. >0.2 ng/ml) were retrospectively evaluated; moreover, biochemical recurrence-free survival (bRFS), cancer specific survival (CSS) and overall survival (OS) in patients who underwent watchful waiting (16 cases), adjuvant (84 cases) and salvage (10 cases) therapy were recorded. Results: A PSA nadir >0.2 ng/ml was correlated with node involvement, Gleason score ≥9, cT2, PSA >20 ng/ml, positive surgical margins and total cancer percentage >20%. At a median follow-up of 90 months (range=10-155 months) bRFS, OS and CSS were 92%, 96% and 80%, respectively. Conclusion: Radical retropubic prostatectomy combined with adjuvant and salvage treatments demonstrated a satisfactory outcome for pT3b prostate cancer.

Original languageEnglish
Pages (from-to)937-942
Number of pages6
JournalAnticancer Research
Issue number2
Publication statusPublished - Feb 1 2014


  • Prostate cancer
  • PT3b outcome
  • PT3b PCa
  • PT3b PSA nadir

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'PSA nadir and outcome in 100 patients with pT3b prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Pepe, P., Improta, G., Fraggetta, F., Emmanuele, C., Simeon, V., Dibenedetto, G., Colecchia, M., & Aragona, F. (2014). PSA nadir and outcome in 100 patients with pT3b prostate cancer. Anticancer Research, 34(2), 937-942.